Publications by authors named "Maize Ducret"
Article Synopsis
- - The study aimed to compare how effective and safe different treatment schedules with azathioprine (AZA) and rituximab (RTX) are in preventing relapses in patients with ANCA-associated vasculitis who are in complete remission.
- - Researchers conducted trials that compared 18-month fixed RTX to AZA, 18-month fixed RTX to 18-month tailored RTX, and extended 36-month RTX therapy versus placebo, tracking patient outcomes over 84 months.
- - Findings indicated that the 18-month fixed RTX regimen was significantly better at preventing major relapses compared to AZA and the tailored RTX approach, leading to a higher remission rate at the 84-month mark.
Objectives: To investigate the effects on health-related quality of life (HRQOL) and functional capability of rituximab vs azathioprine for ANCA-associated vasculitis (AAV) maintenance therapy.
Methods: In a 24-month phase III randomised-controlled trial, 115 patients over time received rituximab or azathioprine for AAV maintenance therapy. Mean changes of 36-item Short-form Health Survey (SF-36) and Health Assessment Questionnaire (HAQ) scores from baseline were analysed.
Background: The combination of cyclophosphamide and glucocorticoids leads to remission in most patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitides. However, even when patients receive maintenance treatment with azathioprine or methotrexate, the relapse rate remains high. Rituximab may help to maintain remission.
View Article and Find Full Text PDF